Long cycle-life wound lithium-ion battery cells having metallized film current collectors
US-2024358635-A1 · Oct 31, 2024 · US
Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias
US12257232B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12257232-B2 |
| Application number | US-202318463707-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 8, 2023 |
| Priority date | Jan 24, 2018 |
| Publication date | Mar 25, 2025 |
| Grant date | Mar 25, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin from T. cacao and showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3 Y367C/+ femurs comparing to Fgfr3 +/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a FGFR3-related chondrodysplasia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a substantially pure (−)-epicatechin in a pharmaceutical composition that does not comprise flavonols, sweroside, hexenyl 5 xylopyranosyl glucopyranoside, procyanidin, catechin, cinchonain, or quercitin. 2. The method of claim 1 wherein the FGFR3-related chondrodysplasia is selected from the group consisting of thanatophoric dysplasia type I, thanatophoric dysplasia type II, hypochondroplasia, achondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans , and hypochondroplasia. 3. The method of claim 1 wherein the step of administering comprises administering to the patient a pharmaceutical composition comprising the substantially pure (−)-epicatechin as an active principle and at least one pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Drugs for skeletal disorders · CPC title
- A61K31/353Primary
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12257232B2 cover?
- FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In att…
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Univ Paris Cite, Fond Imagine, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/353. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).